Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

التفاصيل البيبلوغرافية
العنوان: Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
المؤلفون: Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat
المصدر: Blood. 140:577-578
بيانات النشر: American Society of Hematology, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry
تدمد: 1528-0020
0006-4971
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::adf57cc985ec01eca34b9429987fcb38
https://doi.org/10.1182/blood-2022-156389
رقم الأكسشن: edsair.doi...........adf57cc985ec01eca34b9429987fcb38
قاعدة البيانات: OpenAIRE